Lina GuguchevaCBO at Northern Biologics
Lina Gugucheva joined Northern Biologics as Chief Business Offer in November 2019. Prior to joining Northern, Ms. Gugucheva served as Vice President, Business Development & Strategy at IFM Therapeutics. At IFM, Ms. Gugucheva led the structuring, negotiation and execution of multiple debt and equity financings in excess of $100M across multiple IFM subsidiaries. Ms. Gugucheva also spearheaded IFM’s business development efforts, leading IFM’s negotiations for the successful $1.58B sale of IFM Tre, IFM’s NLRP3 antagonist-focused subsidiary, to Novartis in May 2019, as well as the $880M collaboration and exclusive option agreement between Novartis and IFM Due, IFM’s subsidiary, to develop novel immunotherapies inhibiting the cGAS/STING pathway in August 2019.
Ms. Gugucheva began her career as a life sciences transactional associate at the law firm of Covington & Burling. Ms. Gugucheva was then Vice President, Investments & Counsel at Royalty Pharma where she negotiated a series of transactions including the $2.85 billion purchase of a royalty interest on sales of the multiple sclerosis drug, TYSABRI®. Ms. Gugucheva holds a J.D. from Harvard Law School and a B.A. in molecular biology and political science from New York University.